With the increased number of active centers, the complete enrolment of the European PAES study, and ...
Redeye comments on Hexatronic’s Q1 report, showing a strong development in Data Center but with Fibe...
Redeye updates its view on NextCell following an uneventful Q2 2024/2025 report and the company’s op...
Q1: Sales 4% below, EBITDA NOK 10m vs ABGSCe NOK 4m NOK 10m lower opex explains beat.
Redeye has updated its estimates following Heliospectra’s Q1 2025 report.
Net sales and adjusted EBITDA were below our expectations in Q1, but the company reiterated its clea...
59% y-o-y sales growth for Catalyst in Q1'25e Lower our EBIT forecasts by 12-23% for '25e-'27e Q1'25...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 28 april 2025 att Koncernen förvärv...
Hyresintäkterna steg med hela 72% till 15,6 meur och förvaltningsresultat ökade med nästan 50% till ...
We forecast SEK 30m EBIT for Q1e, up 6x vs. Q1'24 ABGSCe EBIT down on reduced activity assumptions &...
Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system.
Redeye leaves its initial comments on Nanologica following the recent news that Flerie Invest has pa...
Redeye shares its thoughts on today’s news, where the board of directors of Ngenic have decided to f...
Redeye comments on Nitro Games' Q1 2025 report, which came in roughly in line with expectations.
Q1: -18% org. sales growth, -77% adj. EBITA growth, solid cash flow '25e-'27e adj.
